Dapagliflozin effective against obstructive sleep apnoea hypopnea syndrome in diabetics
The sodium glucose co-transporter 2 inhibitor dapagliflozin appears to have therapeutic potential in type 2 diabetes mellitus patients with obstructive sleep apnoea hypopnea syndrome, exerting beneficial effects on apnoea-hypopnea index, hypoxaemia during sleep and daytime sleepiness, as shown in a study.